Bausch Health Companies I... (BHC)
Bid | 6.78 |
Market Cap | 2.67B |
Revenue (ttm) | 9.61B |
Net Income (ttm) | -45.71M |
EPS (ttm) | -0.13 |
PE Ratio (ttm) | -55.92 |
Forward PE | 1.72 |
Analyst | Hold |
Ask | 7.4 |
Volume | 1,294,734 |
Avg. Volume (20D) | 2,619,936 |
Open | 7.18 |
Previous Close | 7.16 |
Day's Range | 7.09 - 7.29 |
52-Week Range | 3.96 - 11.46 |
Beta | 0.60 |
About BHC
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on...
Analyst Forecast
According to 5 analyst ratings, the average rating for BHC stock is "Hold." The 12-month stock price forecast is $8, which is an increase of 10.04% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription

1 week ago · accessnewswire.com
Bausch Health Announces Next Steps in Financing Initiative with J.P. MorganLAVAL, QC / ACCESS Newswire / March 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver bett...

1 month ago · seekingalpha.com
Bausch Health Companies Inc. (BHC) Q4 2024 Earnings Call TranscriptBausch Health Companies Inc. (NYSE:BHC ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Garen Sarafian - IR Thomas Appio - CEO Jean-Jacques Charhon - EVP & CFO Conf...